William J. Gradishar, MD

William J. Gradishar, MD, discusses the choice of adjuvant or neoadjuvant regimens for patients with HER2-positive breast cancer.

William J. Gradishar, MD, discusses the questions ongoing studies are looking to answer in the breast cancer space.

Before closing out their discussion on HER2+ breast cancer, expert oncologists share excitement for emerging treatment strategies and ongoing clinical trials.

A broad review of CNS-related clinical trial data in the setting of HER2+ breast cancer and concurrent brain metastases.

A brief discussion on treatment options available for patients with HER2+ metastatic breast cancer and brain metastases who progress on the HER2CLIMB regimen.

Centering discussion on a patient case of HER2+ breast cancer with brain metastases, experts consider optimal treatment regimens in this setting.

Focusing on the HER2CLIMB regimen, experts consider appropriate treatment options for patients with HER2+ metastatic breast cancer in the third-line setting and beyond.

Expert oncologists share brief notes on their real-world experience managing HER2+ metastatic breast cancer with trastuzumab deruxtecan.

Comprehensive discussion on the presence and management of interstitial lung disease in patients being treated for HER2+ metastatic breast cancer.

Shared insight on the DESTINY-Breast03 trial, which analyzed trastuzumab deruxtecan therapy in patients with HER2+ metastatic breast cancer.

Panelists provide a broad overview of treatment options available for patients diagnosed with HER2+ metastatic breast cancer.

A focused discussion on the subcutaneous formulation of trastuzumab and pertuzumab in patients with early-stage HER2+ breast cancer.

Shifting their focus to the adjuvant setting, expert panelists review the optimal selection of therapy following surgery in early-stage HER2+ breast cancer.

Comprehensive insight on the neoadjuvant treatment armamentarium for early-stage HER2+ breast cancer and the appropriate selection of specific agents.

Centering discussion on a patient case of early-stage HER2+ breast cancer, expert oncologists consider when it is appropriate to utilize neoadjuvant therapy.

William J. Gradishar, MD, discusses the design and results of a study of intravenous versus subcutaneous pertuzumab and trastuzumab in patients with HER2-positive breast cancer.

William J. Gradishar, MD, discusses the current standard of care for patients with HER2-positive breast cancer, as well as some other promising therapies in this space.

William J. Gradishar, MD, discussed the effect tucatinib had on central nervous system metastases in patients with HER2-positive breast cancer.

William J. Gradishar, MD, discusses the NCCN guidelines in regard to selecting molecular assays for patients with breast cancer. Currently, there are 3 available assays that clinicians can order: 21-gene, 50-gene, and 70-gene assays.

William J. Gradishar, MD, deputy director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine, discusses the takeaways from the TransATAC trial, which was a comprehensive comparison of prognostic signatures in breast cancer.

William J. Gradishar, MD, discusses advances in the last year in the treatment of patients with HER2-positive breast cancer.